Scientific Session
Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Christopher Denton, MD, PhD
University College London, UK
Northwood, United Kingdom
Disclosure(s): AbbVie: Consultant (Ongoing); Acceleron: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Arxx Therapeutics: Grant/Research Support (Ongoing); Bayer: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Certa: Consultant (Ongoing); Corbus: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon Therapeutics: Consultant (Ongoing); Inventiva: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Consultant (Ongoing); Roche: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Servier: Grant/Research Support (Ongoing), Grant/Research Support (Ongoing)